Videos

Marwan G. Fakih, MD, discusses barriers that create treatment differences in metastatic colorectal cancer for community oncologists.

Enzalutamide's efficacy is supported by preference studies and a MAIC, helping doctors and patients make informed treatment choices.

Without head-to-head trials, doctors balance MAIC efficacy data with factors like cost and safety to choose the best ARPI for each patient.

A statistical analysis (MAIC) of the ARCHES and ARANOTE studies suggests enzalutamide is more effective at delaying disease progression.

With no head-to-head trials for ARPIs, physicians use methods like MAIC to indirectly compare efficacy and safety, guiding treatment decisions.

Enzalutamide and other ARPIs are key in treating metastatic prostate cancer by blocking androgen receptors, improving patient survival rates.

An expert discusses the evolving landscape of large B-cell lymphoma (LBCL) treatment, highlighting emerging CAR T-cell targets and bispecific antibody strategies, the potential shift toward more personalized, less toxic therapies, and the ongoing challenges of improving patient access, referral, and posttreatment management to maximize outcomes.

An expert discusses the emerging role of bispecific antibodies in lymphoma treatment, highlighting their expanding use across treatment lines—including as alternatives or bridges to CAR T-cell therapy—their promising efficacy, more manageable toxicity profiles, and potential to improve patient quality of life through flexible care models.

An expert discusses the advances in managing CAR T-cell therapy toxicities, emphasizing aggressive early treatment of acute complications, the importance of coordinated long-term monitoring with community providers, and how real-world data validate the therapy’s safety and effectiveness across diverse patient populations.

Zanidatamab demonstrates an impressive 41% response rate and a 1-year duration of response in a large phase 2 BTC trial, offering a promising new option.

Zanidatamab, a bispecific HER2 antibody, shows promise in biliary tract cancer by requiring high HER2 expression and cross-linking receptors for efficacy.

Despite a poor prognosis and resistance to chemotherapy, new targeted therapies based on genetic mutations are improving outcomes for patients with biliary tract cancer.

An expert highlights how optimizing CAR T-cell therapy requires simplifying the treatment process, reducing insurance delays, addressing that 40% to 50% of patients may need further therapy, managing long-term immune and safety concerns, investigating risks like second malignancies, and enhancing collaboration between treatment centers and local providers to improve patient experience and outcomes.

An expert explains that T-cell fitness is critical for CAR T-cell therapy success, as earlier use—before multiple rounds of chemotherapy or bispecific antibody exposure—helps preserve T-cell quality and function, thereby improving response rates and long-term outcomes; consequently, early referral for CAR T is recommended to optimize treatment effectiveness.

An expert discusses that while CAR T-cell therapies carry risks such as cytokine release syndrome and neurotoxicity, advancements in supportive care and monitoring have significantly improved their safety profiles—allowing clinicians to tailor product selection, such as favoring axi-cel for rapidly progressing disease due to its survival benefit and quick manufacturing, or liso-cel for more frail patients requiring lower toxicity exposure.

An expert discusses the complexities of sequencing antibody-drug conjugates (ADCs) in metastatic triple-negative breast cancer, emphasizing the need for biomarker-driven treatment personalization and crossover trial designs to optimize early use and improve patient outcomes.

George Mulligan, PhD, discusses the ODAC's review of daratumumab for high-risk smoldering multiple myeloma, noting its efficacy in delaying progression but raising questions about patient criteria.

An expert discusses the selection of CAR T-cell therapies for third-line large B-cell lymphoma (LBCL), noting that while all approved products show comparable efficacy, differences in co-stimulatory domains, toxicity profiles, manufacturing timelines, and patient-specific factors guide individualized treatment decisions.

An expert discusses the transformative impact of CAR T-cell therapy in relapsed/refractory large B-cell lymphoma, highlighting long-term data that support durable remission—and potential cure—for a subset of patients, while emphasizing its favorable long-term safety profile and growing role in the evolving standard of care.

Bradley A. McGregor, MD, discusses the advancements in treating metastatic renal cell carcinoma.

Jacob Sands, MD, discusses the benefits of the arrival of Dato-DXd into the EGFR-positive non–small cell lung cancer treatment landscape and the next steps in research for this agent.

Jacob Sands, MD, discusses anaging Dato-DXd toxicities like stomatitis, eye irritation, and interstitial lung disease, which involves tailored strategies including rinses, eye drops, and close monitoring.

Panelists discuss how future research priorities include developing predictive biomarkers, exploring quadruple therapy combinations, determining optimal checkpoint inhibitor duration and sequencing strategies, incorporating immunotherapy into earlier treatment lines with chemoradiation, and utilizing circulating tumor DNA for prognostic monitoring after definitive therapy.

Jacob Sands, MD, discusses the data that support the FDA accelerated approval of Dato-DXd in EGFR-positive non–small cell lung cancer.

An expert discusses that while the liso-cel trial did not show a statistically significant overall survival benefit—likely due to its small sample size and crossover design—it still demonstrated durable responses with a favorable safety profile, offering a valuable, lower-toxicity CAR T option for patients with relapsed or refractory large B-cell lymphoma, particularly those less suited for more aggressive therapies like axi-cel.

An expert discusses how the ZUMA-7 trial marked a pivotal shift in the treatment of primary refractory diffuse large B-cell lymphoma by demonstrating that second-line CAR T-cell therapy not only improves overall survival compared with standard care but also leads to faster functional recovery, reinforcing the importance of early referral and positioning CAR T as a preferred curative-intent option rather than a last resort.

Katherine McDaniel, MD, a reproductive endocrinologist, discusses the key takeaways for oncologists treating patients of reproductive age.

Katherine McDaniel, MD, discusses the barriers to fertility preservation access for patients diagnosed with cancer.

Panelists discuss how future directions in chronic lymphocytic leukemia (CLL) treatment include promising developments with Bruton tyrosine kinase (BTK) degraders, noncovalent BTK inhibitors, alternative BCL2 inhibitors like sonrotoclax, bispecific antibodies for consolidation strategies, and addressing remaining gaps such as Richter transformation risk, infection susceptibility, and secondary malignancy surveillance in this rapidly evolving therapeutic landscape.

Panelists discuss how real-world evidence studies from databases like Flatiron demonstrate that second-generation Bruton tyrosine kinase (BTK) inhibitors perform better than first-generation agents in clinical practice, providing hypothesis-generating data that support clinical observations about treatment tolerability and infection rates, although these retrospective analyses should complement rather than replace randomized controlled trial evidence.